Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 132 publications.

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.

Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M, Davenport E, Guana A, Reich K. Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.

Puig L, Sofen H, Augustin M, Abramovits W, Kingo K, Gilloteau I, Zhao Y, Mordin M, Williams N, Guana A, Korman N. Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.

Lebwohl M, Blauvelt A, Augustin M, Zhao Y, Gilloteau I, Herrera V, Milutinovic M, You R, Mordin M, McLeod L, Strober B. Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling. Poster presented at the 2016 AAD Summer Meeting; July 2016. Boston, MA.

Mordin M, Haydysch E, Graham-Clarke CP, Gnanasakthy A, Nikai E. Patient perceptions of psoriasis: a review of the survey literature by geography. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A126-7.

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049

Gnanasakthy A, Mordin M, Haydysch E, DeMuro C. FDA patient-reported outcome labeling of novel therapies (2011-2015). Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 25, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A285-6.

Puig L, Mordin M, Mollon P, Williams N, Fox T, Papavassilis C, Strober B. Disease burden in patients with severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB243. doi: 10.1016/j.jaad.2016.02.952

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236

Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassils C, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl M. Psychometric validation of the psoriasis symptom diary using phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016 Mar;55(3):e147-55. doi: 10.1111/ijd.13117

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 15th Annual Caribbean Dermatology Symposium; January 26, 2016. Grand Cayman. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 12th Annual Maui Derm for Dermatologists 2016 Conference; January 25, 2016. Maui, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the Winter Clinical Dermatology Conference; January 15, 2016. Kauai, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 12, 2015. Orlando, FL. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

McLeod L, Mallya AG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 2015. Orlando, FL. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Strober B, Mordin M, Mollon, P, Williams N, Fox T, Papavassilis C, Lebwohl M. Secukinumab demonstrates greater impact on patient global impression of change than etanercept in moderate to severe psoriasis. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA Annual Summer Dermatology Conference 2015; June 4, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Mordin M, Brown TM, McLeod L, DeMuro C, Gnanasakthy A. Two companies following the FDA pro guidance leads to similar but different measures: a case study in psoriasis. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Lebwohl M, Gottlieb AB, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod LD, Mordin MM, Nelson LM, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the Psoriasis Symptom Diary from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015. San Francisco, CA.

McLeod LD, Mallya U, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis skin clearance for patients who achieved PASI 90 provides greater HRQOL improvements than those achieved PASI 75-89. Poster presented at the Maui Derm for Dermatologists 2015; January 25, 2015. Maui, HI.

McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI 90 response achieve greater health-related quality of life improvements than those with PASI 75-89 response. Poster presented at the 2015 Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI.

Brogan AP, Hogue SL, Mordin MM, Kwong J. United States decision maker perceptions of data from observational studies and other health economics and outcomes research. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.

Coles TM, Dwyer K, Mordin MM, Williams VS, Clatworthy M, Yates P, Hamilton B. Psychometric evaluation of the patients's Knee Implant Performance (PKIP) questionaire for the assessment of primary total knee arthroplasty. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150

Lebwohl M, Mordin MM, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2, 2014. Amsterdam, The Netherlands.

Copley-Merriman C, Zelt S, Stone G, Barrows SM, Mordin MM, Hogue SL. Emerging-market payer needs: how should these countries be included in dermatology drug development plans? Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl MG. Psychometric evaluation of the Psoriasis Symptom Diary using phase 3 trial data. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 Jun; 17(3):A288. doi: 10.1016/j.jval.2014.03.1676

Lebwohl M, Karpov A, Zhao Y, Mordin MM, Elewski B. Secukinumab impact on patient-reported psoriasis symptoms: an analysis of the psoriasis symptom diary (ERASURE study). Poster presented at the Society of Dermatology Physicians Assistants Annual Summer Dermatology Conference; May 29, 2014. Indianapolis, IN.

Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006

DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health. 2013 Dec;16(8):1150-5. doi: 10.1016/j.jval.2013.08.2293

Gnanasakthy A, Lewis S, Clark M, Mordin M, DeMuro C. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health Qual Life Outcomes. 2013 May 15;11:83.

Mordin M, Hogue S, Barrows S, van Amerongen D. Safe and effective versus reasonable and necessary: is the deck stacked against medical devices? Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):246.

Mordin M, Copley-Merriman C, Mauskopf J, Sweeney C, Bhattacharyya S, Farup C, Beach W, Higgins L, McIntyre L. Surgical innovation: do we need a more balanced framework for evidence? Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 3, 2013. [abstract] Value Health. 2013 May; 16(3):A247.

McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.

Gnanasakthy A, DeMuro-Mercon CJ, Clark MJ, Mordin MM, Thomas S. Role of patient-reported outcome measures in the assessment of central nervous system agents. Ther Innov Regul Sci. 2013;47(5):613-8.

Mauskopf J, Beach W, McIntyre L, Bhattacharyya S, Higgins L, Mordin M, Copley-Merriman K. Evidence-based medicine: a case study of its application to innovative surgical procedures in the United Kingdom. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 7, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A408.

Gnanasakthy A, Doward L, Clark M, Mordin M, DeMuro C. Concordance of pro labeling claims between the FDA and EMA. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A321.

Mordin M, Clark M, Doward L, Willian M. Pediatric patient-reported outcomes assessment: a case study in epidermolysis bullosa. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A480-1.

Engelhart L, Nelson L, Lewis S, Mordin M, Demuro-Mercon C, Uddin S, McLeod L, Cole B, Farr J. Knee injury and osteoarthritis outcome score subscales for patients with articular cartilage lesions of the knee. Am J Sports Med. 2012 Oct 1;40(10):2264-72.

Lewis S, Price M, Mordin M, Dwyer K, Heekin R, Yates P, O'Brien S, Beverland D. Assessing performance following primary total knee arthroplasty: development of the patient's knee implant performance (PKIP) measure. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. [abstract] Value Health. 2012 Jun 1; 15(4):A70.